RBC Capital Reiterates Buy Rating on uniQure N.V.
RBC Capital maintains its buy rating on uniQure N.V. with a $65 price target, a 36.15% upside from the current price.
Key Points
- RBC Capital reiterated its buy rating on uniQure N.V. with a $65 price target on June 18, 2026.
- RBC Capital's $65 price target implies 36.15% upside from uniQure N.V.'s ($QURE) current $47.74 share price.
- uniQure N.V. trades at $48.16, with a market cap of about $3.04 billion, despite not being profitable.
- Analysts generally hold a buy consensus on uniQure, with a mean target price of $38.78 across 11 opinions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
RBC Capital reiterated its buy rating on uniQure N.V. (NasdaqGS: QURE) on June 18, 2026, maintaining a price target of $65. Analyst Luca Issi's continued support for the biotechnology company highlights ongoing confidence in its potential.
Other Institutional Activity in uniQure
Several other institutional investors have also been active in uniQure. Avoro Capital Advisors LLC reduced its holding by 190,405 shares, ending with 5,959,595 shares valued at about $97.4 million. Aberdeen Group PLC, on the other hand, increased its position by 1,627,746 shares, totaling 5,306,386 shares worth approximately $86.8 million. JPMorgan Chase & Co trimmed its holdings by 97,160 shares, resulting in 2,837,466 shares valued at $41.8 million. Two Sigma Investments, LP boosted its stake by 1,224,587 shares, reaching 2,675,871 shares worth around $43.8 million.
uniQure N.V. Stock Down 2.0%
Shares of NasdaqGS:QURE traded near $48.16. uniQure has a market cap of approximately $3.04 billion. While the company is not currently profitable, it carries a forward P/E ratio of -17.06. The stock has experienced a 52-week low of $8.73 and a high of $71.50, with a 50-day moving average of $23.52 and a 200-day moving average of $27.38. The firm's current ratio stands at 10.40, indicating strong liquidity, though its debt-to-equity ratio is high at 365.37.
$QURE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its latest earnings, uniQure reported revenue of $18.1 million, reflecting growth of 1.27%. Despite this revenue increase, the company has a net margin of 0.0% and a return on equity of -228.24%. The next earnings report is expected on July 29, 2026.
Insider Buying and Selling at uniQure N.V.
Recent insider activity at uniQure saw various transactions. On June 15, 2026, Balachandran Madhavan sold 10,000 shares at an undisclosed price and also bought 10,000 shares at $8.49. Jeannette Potts, the Chief Legal Officer, sold 5,237 shares at $27.67 on the same day. Earlier, on June 11, 2026, Rachelle Suzanne Jacques and Robert Gut each sold shares at $27.06 under planned transactions.
Analysts Set New Price Targets
On June 18, 2026, RBC Capital maintained its buy rating on uniQure, with a price target of $65. Other analysts have also shown support: HC Wainwright & Co. maintained a buy rating with a $50 target on May 6, 2026, while Chardan Capital set a $37 target on April 30, 2026. The overall analyst consensus is a buy, with a mean target price of $38.78 from 11 opinions.
About uniQure N.V.
uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focusing on developing gene therapies for rare and severe diseases. Its flagship product, HEMGENIX, helps hemophilia B patients reduce bleeding risks. The company is advancing several gene therapy candidates, including AMT-130 for Huntington's disease and AMT-260 for epilepsy. Led by CEO Matthew Craig Kapusta, uniQure employs 221 people.
Bottom Line
RBC Capital's reiteration of its buy rating for uniQure underscores continued confidence in the company's innovative therapies. While the firm isn't yet profitable, its strong liquidity position and robust pipeline attract investor attention. As always, it's important to remember that analyst ratings and institutional filings are backward-looking and may not reflect current market conditions.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.